Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MiNK Therapeutics

< Previous 1 2 Next >
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Reports Second Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Reports First Quarter 2024 Results
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
From MiNK Therapeutics
Via GlobeNewswire
Tickers INKT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.